EVLO insider filings
Evelo Biosciences, Inc. — 38 most recent insider filings (SEC Forms 3/4/5) from EDGAR, normalized by FilingPulse. Latest filing: 2023-11-08. Screen EVLO transaction legs live →
Insider transaction summary — last 90 days
No insider filings (Forms 3/4/5) for EVLO between 2026-07-10 and 2026-10-08. The table below lists the most recent filings on record.
Recent insider filings — Evelo Biosciences, Inc.
| Filed | Form | Insider | Reported transactions | Source |
|---|---|---|---|---|
| 2023-11-08 | 4 | Bodmer Mark — CSO, President of R&D | Option exercise (M): 6,625 · Sale (S): 3,163 @ $0.33 · Option exercise (M): 6,625 (derivative) @ $0 | EDGAR |
| 2023-11-08 | 4 | McHale Duncan — Chief Medical Officer | Option exercise (M): 6,500 · Sale (S): 3,103 @ $0.33 · Option exercise (M): 6,500 (derivative) @ $0 | EDGAR |
| 2023-11-08 | 4 | Thorell Marella — Chief Financial Officer | Option exercise (M): 6,500 · Sale (S): 1,811 @ $0.33 · Option exercise (M): 6,500 (derivative) @ $0 | EDGAR |
| 2023-11-08 | 4 | GILL SIMBA — President & CEO, Director | Option exercise (M): 1,172 · Sale (S): 172 @ $0.33 · Option exercise (M): 1,172 (derivative) @ $0 | EDGAR |
| 2023-11-03 | 4 | Bodmer Mark — CSO, President of R&D | Option exercise (M): 12,500 · Sale (S): 6,854 @ $0.33 · Option exercise (M): 12,500 (derivative) @ $0 | EDGAR |
| 2023-11-03 | 4 | McHale Duncan — Chief Medical Officer | Option exercise (M): 12,500 · Sale (S): 6,854 @ $0.33 · Option exercise (M): 12,500 (derivative) @ $0 | EDGAR |
| 2023-11-03 | 4 | Thorell Marella — Chief Financial Officer | Option exercise (M): 12,500 · Sale (S): 3,999 @ $0.33 · Option exercise (M): 12,500 (derivative) @ $0 | EDGAR |
| 2023-09-29 | 4 | GILL SIMBA — President & CEO, Director | Option exercise (M): 15,000 · Sale (S): 1,996 @ $3.94 · Grant/award (A): 60,000 (derivative) @ $0 · Option exercise (M): 15,000 (derivative) @ $0 | EDGAR |
| 2023-09-13 | 4 | Bodmer Mark — CSO, President of R&D | Grant/award (A): 37,500 (derivative) @ $0 | EDGAR |
| 2023-09-13 | 4 | Thorell Marella — Chief Financial Officer | Grant/award (A): 37,500 (derivative) @ $0 | EDGAR |
| 2023-09-13 | 4 | McHale Duncan — Chief Medical Officer | Grant/award (A): 37,500 (derivative) @ $0 | EDGAR |
| 2023-08-09 | 4 | Bodmer Mark — CSO, President of R&D | Option exercise (M): 6,625 · Sale (S): 3,128 @ $9.51 · Option exercise (M): 6,625 (derivative) @ $0 | EDGAR |
| 2023-08-09 | 4 | McHale Duncan — Chief Medical Officer | Option exercise (M): 6,500 · Sale (S): 3,434 @ $9.51 · Option exercise (M): 6,500 (derivative) @ $0 | EDGAR |
| 2023-08-09 | 4 | Thorell Marella — Chief Financial Officer | Option exercise (M): 6,500 · Sale (S): 2,004 @ $9.51 · Option exercise (M): 6,500 (derivative) @ $0 | EDGAR |
| 2023-08-09 | 4 | GILL SIMBA — President & CEO, Director | Option exercise (M): 1,171 · Sale (S): 342 @ $9.51 · Option exercise (M): 1,171 (derivative) @ $0 | EDGAR |
| 2023-07-13 | 4 | Flagship Ventures Fund IV General Partner LLC — 10% owner Flagship Ventures Fund IV, L.P. — 10% owner Nutritional Health LTP Fund General Partner LLC — 10% owner Nutritional Health LTP Fund, L.P. — 10% owner Flagship Pioneering Inc. — 10% owner Flagship Pioneering Fund VII General Partner LLC — 10% owner Flagship Pioneering Fund VII, L.P. — 10% owner AFEYAN NOUBAR — 10% owner | Purchase (P): 1,082,251 @ $2.31 · Purchase (P): 1,082,251 @ $2.31 · Purchase (P): 3,246,753 @ $2.31 | EDGAR |
| 2023-07-12 | 4 | Reynolds Alexander C — Director | Grant/award (A): 2,000 (derivative) @ $0 | EDGAR |
| 2023-07-12 | 4 | Moore Jeffrey R. — Director | Grant/award (A): 2,000 (derivative) @ $0 | EDGAR |
| 2023-06-12 | 4 | Williams Tonya — Director | Grant/award (A): 20,000 (derivative) @ $0 | EDGAR |
| 2023-06-12 | 4 | Hohneker John — Director | Grant/award (A): 20,000 (derivative) @ $0 | EDGAR |
| 2023-06-12 | 4 | McInnes Iain B. — Director | Grant/award (A): 20,000 (derivative) @ $0 | EDGAR |
| 2023-06-12 | 4 | Andres Juan — Director | Grant/award (A): 20,000 (derivative) @ $0 | EDGAR |
| 2023-06-12 | 4 | Bodmer Mark — CSO, President of R&D | Sale (S): 22,571 @ $0.14 | EDGAR |
| 2023-06-12 | 4 | Gutierrez-Ramos Jose-Carlos — Director | Grant/award (A): 20,000 (derivative) @ $0 | EDGAR |
| 2023-06-12 | 4 | Rosiello Robert L. — Director | Grant/award (A): 30,000 (derivative) @ $0 | EDGAR |
| 2023-06-12 | 4 | McHugh Julie — Director | Grant/award (A): 20,000 (derivative) @ $0 | EDGAR |
| 2023-06-12 | 4 | MELAS KYRIAZI THEO — Director | Grant/award (A): 20,000 (derivative) @ $0 | EDGAR |
| 2023-06-12 | 4 | GILL SIMBA — President & CEO, Director | Grant/award (A): 1,000,000 (derivative) @ $0 | EDGAR |
| 2023-05-10 | 4 | McHale Duncan — Chief Medical Officer | Sale (S): 66,730 @ $0.13 | EDGAR |
| 2023-05-10 | 4 | Bodmer Mark — CSO, President of R&D | Sale (S): 68,014 @ $0.13 | EDGAR |
| 2023-05-10 | 4 | Thorell Marella — Chief Financial Officer | Sale (S): 38,531 @ $0.13 | EDGAR |
| 2023-05-10 | 4 | GILL SIMBA — President & CEO, Director | Sale (S): 3,537 @ $0.13 | EDGAR |
| 2023-05-10 | 4/A | GILL SIMBA — President & CEO, Director | Option exercise (M): 23,437 (derivative) @ $0 | EDGAR |
| 2023-05-09 | 4 | Thorell Marella — Chief Financial Officer | Option exercise (M): 130,000 · Option exercise (M): 130,000 (derivative) @ $0 | EDGAR |
| 2023-05-09 | 4 | Bodmer Mark — CSO, President of R&D | Option exercise (M): 132,500 · Option exercise (M): 132,500 (derivative) @ $0 | EDGAR |
| 2023-05-09 | 4 | McHale Duncan — Chief Medical Officer | Option exercise (M): 130,000 · Option exercise (M): 130,000 (derivative) @ $0 | EDGAR |
| 2023-05-09 | 4 | GILL SIMBA — President & CEO, Director | Option exercise (M): 23,437 · Option exercise (M): 23,437 (derivative) @ $0 | EDGAR |
| 2023-04-18 | 4 | Rosiello Robert L. — Director | Grant/award (A): 40,000 (derivative) @ $0 | EDGAR |
Recent 8-K events — Evelo Biosciences, Inc.
| Filed | Form | Items reported | Source |
|---|---|---|---|
| 2024-01-26 | 8-K | 5.07 — Submission of Matters to a Vote of Security Holders | EDGAR |
| 2023-12-04 | 8-K | 3.01 — Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing | EDGAR |
| 2023-11-21 | 8-K | 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2023-10-27 | 8-K | 1.01 — Entry into a Material Definitive Agreement 9.01 — Financial Statements and Exhibits | EDGAR |
| 2023-10-17 | 8-K | 8.01 — Other Events | EDGAR |
| 2023-08-21 | 8-K | 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2023-08-14 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2023-07-20 | 8-K | 1.01 — Entry into a Material Definitive Agreement 1.02 — Termination of a Material Definitive Agreement 9.01 — Financial Statements and Exhibits | EDGAR |
| 2023-07-12 | 8-K | 1.01 — Entry into a Material Definitive Agreement 7.01 — Regulation FD Disclosure 9.01 — Financial Statements and Exhibits | EDGAR |
| 2023-07-10 | 8-K | 1.01 — Entry into a Material Definitive Agreement 3.02 — Unregistered Sales of Equity Securities 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers 7.01 — Regulation FD Disclosure 9.01 — Financial Statements and Exhibits | EDGAR |
Need this as JSON?
GET https://api.filingpulse.io/v1/insider-trades?ticker=EVLO returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new ones to you in seconds. API docs →